FDA Urges Centralized Clinical Trial Monitoring Over Frequent On-Site Visits - Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Recent Duke University survey found that firms predominately conduct frequent visits to each clinical investigator site but "the rationale behind any specific monitoring approach does not appear to be evidence-based."